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Abstract
Background: The aim of the following study is to evaluate the advancement of incidentally diagnosed prostate
cancer in specimen after cystoprostatectomies caused by muscle-invasive bladder cancer. Secondly we assessed
the survival in patients after radical cystoprostatectomy whose postoperative specimen was characterized by the
presence of co-existing prostate cancer or prostate infiltration by urothelial bladder cancer.
Methods: Between 1993 and 2009 a total of 320 patients with muscle-invasive bladder cancer underwent
cystoprostatectomy. The first analyzed group consisted of 52 patients with bladder cancer infiltrating prostate,
while the second group consisted of 21 patients with co-existing prostate cancer. In all patients cancer specific
survival and progression were analyzed. Average follow up was 75.2 months (range: 0 - 181).
Results: Cancer-specific survival was significantly shorter in group I (p = 0.03). Neoplastic progression in patients
from group I was observed in 42.2% of patients, while in patients from group II in 23.6% of patients (p = 0.04). No
statistical difference was observed in the percentage of positive lymph nodes between the groups (p = 0.22). The
median Gleason score in patients with co-existing prostate cancer was equal to 5. The stage of prostate cancer
pT2/pT3 was equal to 20 (96%)/1 (4%) patients. 12 (57%) prostate cancers were clinically insignificant. Biochemical
recurrence occurred in 2 (9%) patients.
Conclusions: 1. Incidentally diagnosed prostate cancer in specimen after cystoprostatectomies is frequently
clinically insignificant and characterized by low progression.
2. Patients with bladder cancer infiltrating prostate are characterized by higher percentage of progression and
death in comparison with patients with co-existing prostate cancer.
Background
Cystoprostatectomy is a treatment of choice in men suf-
fering from muscle-invasive bladder cancer. However,
this treatment involves the risk of complications like
incontinence, sexual and metabolic disorders [1].
Complete histopathologic examination not only
enables evaluating the stage and grade of the bladder
cancer, but also the prostate. This is extremely impor-
tant because in autopsy examinations in 30% of men up
t ot h ea g eo f5 0 ,s i n g l ec a n c e rc e l l sa r ef o u n di nt h e
prostate. The percentage in 80-year-old men becomes
higher, up to 70% [2].
Incidental prostate cancers of that type are usually
clinically insignificant, quite well differentiated, not
exceeding the border of the prostate capsule and diag-
nosed in 5 - 36% of cases [3,4]. The frequency of
urothelial cancer infiltration of the prostate is equal to
5 - 40% [5].
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advancement of the bladder cancer is higher than it was
supposed during preoperative examinations. Most often
the histopathologic diagnosis either:
1. confirms the urothelial cancer infiltration of the
prostate and even urethra, or
2. confirms the diagnosis of independently co-existing
prostate cancer.
Both situations are unfavorable prognostic factors for
the operated patient. A high percentage of complications
after cystoprostatectomy forced the urologists to search
for the new sparing operative techniques, namely,
cystectomies sparing the prostate capsule, its apex or
the whole prostate gland [1,6,7]. Nevertheless such treat-
ment carries the risk of non-radical cancer removal [8].
In the situation where removal of the bladder without
removing the prostate is becoming more and more fash-
ionable and frequently utilized, a question concerning
the clinical significance of the abovementioned changes
arises. The aim of the following study is to evaluate the
advancement of incidentally diagnosed prostate cancer
in specimen after cystoprostatectomies caused by mus-
cle-invasive bladder cancer. Another aim of the research
was to evaluate the survival in patients after radical
cystoprostatectomy whose postoperative specimen was
characterized by the presence of co-existing prostate
cancer or infiltration of the prostate by urothelial
cancer.
Methods
The study has been approved by the Silesian Medical
University Ethics Committee and has therefore been
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki. All patients
gave their informed consent prior to their inclusion in
the study.
In the period of time between December 1993 and
March 2009 in the Department of Urology of the Medi-
cal University in Zabrze and the Urologic Department
of the Provincial Hospital in Bielsko-Biała 320 patients
with bladder cancer underwent cystoprostatectomy. 77
patients were subject of the current analysis. The
patients were divided into two groups. The first one
consisted of 52 patients with bladder cancer infiltrating
prostate, while the second group consisted of 21 patients
with co-existing prostate cancer. 4 patients were diag-
nosed with both co-existing prostate cancer and bladder
cancer infiltrating prostate. These 4 patients were
excluded from the research in the evaluation of survival.
21 patients from the second group accounted for 6.5%
of all men with bladder cancer treated in the evaluated
period of time in both centers.
None of the patients was subject to neoadjuvant ther-
apy. In 14 (18.1%) patients orthotopic intestinal bladder
was made, in 29 (37.6%) ureterocutaneostomies and in
34 (44.1%) ileal conduit. None of the analyzed patients
died during the operation. According to the 2002 TNM
classification the infiltration of prostate by urothelial
bladder cancer means stage pT4a. Co-existing prostate
cancer was considered insignificant if all of the features
were observed: preoperative PSA < 10 ng/ml, Gleason
score < 7, cancer lesion less than 0,5 ml and stage pT2
(organ-confined). Whole-mount sectioning of the pros-
tate was conducted by 2 pathologists.
Patients after the surgery were monitored every
3 months during first year, for another 2 years - every
6 months and once a year 3 years after the surgery.
Control tests included creatinine concentration, electro-
lytes, PSA concentration, urine stasis in the upper urin-
ary tract (ultrasonography), chest radiography and
pelvic/abdominal CT once a year.
In all patients the following criteria were analyzed:
age, cancer specific survival, the frequency of complica-
tions and deaths, local recurrences, positive surgical
margins, distant metastases, adjuvant chemotherapy,
number of lymph nodes dissected and creatinine con-
centration before and after the surgery. Biochemical
recurrence of prostate cancer was diagnosed if two con-
secutive serum PSA tests exceeded the level of 0.2 ng/
ml. Survival time was 0 - 181 months (on average:
75.2 months).
The statistical analysis was performed by means of
Statistica Statsoft v. 8.0. For continuous variables
U-Mann-Whitney test was used. For categorical vari-
ables the Chi-square test was applied. Kaplan-Meier
curves were used for the evaluation of cancer-specific
survival with log-rank test. Proportional hazard (Cox)
regression model was used to assess the influence of
stage (T), grade (G), positive nodes (N), positive surgical
margin, adjuvant chemotherapy and coexisting prostate
cancer or pT4a bladder cancer on cancer specific
survival.
Results
The average age of operated patients in group I was 62.7
years, while in group II 67.4 years. The difference was at
the verge of statistical significance (p = 0.06).
The stage was obviously significantly higher in group I
(p < 0.001). However, no significant statistical difference
was observed in the percentage of positive lymph nodes
49.9% vs. 47.5% respectively (p = 0.22) (see table 1). Sur-
vival time was significantly shorter in group I (p = 0.03,
see figure 1). Deaths also occurred more frequently in
group I at the verge of statistical significance (p = 0.07).
Proportional hazard (Cox) regression showed statistically
significant influence of stage (HR: 1.2; p = 0.04), positive
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existing prostate cancer/pT4a bladder cancer (HR: 2.2;
p = 0.04), adjuvant chemotherapy (HR: 1.1; p = 0.02)
and positive surgical margin (HR: 1.2; p = 0,03) on can-
cer-specific survival.
In our study 50 patients (96,1%) had positive cysto-
scopy in terms of prostate infiltration prior to bladder
removal.
Generally, neoplastic progression in patients from
group I after 60.5 months of observation was equal to
42.2%, while in patients from group II after 83.6 months
of observation - 23.6% (p = 0.04). However, no statistical
significance concerning individually the percentage of
distant metastases, complications after the surgery or
local recurrences was observed. The average creatinine
concentration in group I before the surgery was 1.31
mg/dl and 1.19 mg/dl after the surgery (p = 0.12). The
average creatinine concentration in group II before the
surgery was 1.35 mg/dl and 1.15 mg/dl after the surgery
(p = 0.11).
In group II prostate cancer was characterized by high his-
topathologic differentiation and low clinical advancement.
Table 1 Comparison of patients with bladder cancer infiltrating prostate (group I) and co-existing with prostate cancer
(group II)
Group I (n = 52) Group II (n = 21) p value
Age 62.7 67.4 0.06
pT 1 0 3 (14,2%) < 0.001
2 0 7 (33.3%)
3 0 11 (52.3%)
4a 52 (100%) 0
N 0 26 (50%) 11 (52.3%) 0.22
1 2 (3.8%) 3 (14.2%)
2 24 (46.1%) 7 (33.3%)
G 1 5 (9.6%) 4 (19%) 0.16
2 20 (38.4%) 11 (52.3%)
3 27 (51.9%) 6 (28.5%)
Creatinine concentration before the surgery (mg/dl) 1.31
(0.78-3.65)
1.35
(1.05-1.98)
0.69
Figure 1 Cancer specific survival (Kaplan-Meier curves) of the analyzed patients (log-rank test p = 0,04).
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prostate cancer was equal to 5. The stage of prostate cancer
pT2/pT3 was diagnosed in 20 (96%)/1 (4%) patients.
12 (57%) prostate cancers were clinically insignificant.
4 patients excluded from the research (with co-exist-
ing prostate cancer and prostate infiltration by urothelial
bladder cancer) had cancer-specific survival comparable
with group I (log rank; p = 0,8). In 2 (50%) of them
prostate cancer was clinically insignificant. 2 (8%)
patients had prostate cancer with score ≥7 in Gleason
scale. Interestingly, both patients were also diagnosed
with infiltration of prostate by urothelial bladder cancer.
After almost 7 years of postoperative observation in
patients from group II PSA concentration ranged
between 0.04 and 2.9 ng/ml (on average 0.25 ng/ml).
Biochemical recurrence occurred in 2 (9%) patients, in
both of them 5 years after the surgery (PSA concentra-
tion - 2.9 and 2.0 ng/ml respectively). Complications in
the form of pyelonephritis in 5 patients, intestinal fistula
- 1 patient, the narrowing of the anastomosis of the ure-
thra and the bladder (1 patient), postoperative obstruc-
tion (1 patient) or bleedings (2 patients) occurred only
in group I (see table 2).
Discussion
Cystoprostatectomy carries the risk of several functional
complications like urinary incontinence and erection
disorders.
The studies show that during the day incontinence
occurs in 5 - 18% of patients, while at night in 13 - 27%
of patients. Erectile dysfunction appears in 75 - 80% of
patients [9]. In a situation when organ sparing surgeries,
protecting the patient’s basic vital functions, are becom-
ing more and more fashionable and frequently utilized,
a question concerning the oncological radicality of the
abovementioned procedure arises. Close monitoring of
such patients with regard to local recurrence and distant
metastases is crucial, taking into account the fact that
majority of local relapses occur within the first 2 years
after the surgery. The relapse is diagnosed in about 10%
of patients [10-12]. The frequency of distant metastases
after organ sparing surgeries is estimated at 32 - 34%
[10,13]. In the following research the frequency of local
recurrences in patients with pT4 was 4.8%, while the
frequency of distant metastases was equal to 9.6%. The
frequency of prostate infiltration by urothelial cancer, as
has already been stated in the introduction, is estimated
at 5 - 40% [5]. It has to be stressed that primary urothe-
lial cancer can very rarely develop in the prostatic part
of the urethra. Such situation occurs in 1 - 4% of
patients with transitional cell carcinoma [14]. It seems
that the diagnosis of carcinoma in situ or multifocal car-
cinoma is a prognostic factor of infiltration the prostate
by bladder cancer [15]. Why is the diagnosis of prostate
infiltration by urothelial cancer so essential? The answer
to the question lies in the analysis of cancer-specific
survival (see figure 1 and proportional hazard regres-
sion), though some authors emphasize the fact that the
infiltration of excretory ducts by urothelial cancer is not
an unfavorable phenomenon in comparison to the infil-
tration of the prostatic stroma [16]. It seems that the
best way to evaluate the infiltration of prostrate by
urothelial cancer before operation is to use diagnostic
cystoscopy. The risk of failure to diagnose the infiltra-
tion in that type of examination is really low, equal to
3.1% [15]. In our centre each patient undergoes cysto-
scopy before the operation of bladder removal. In our
study 50 patients (96,1%) had positive cystoscopy in
terms of prostate infiltration prior to bladder removal.
The range of urethra’s infiltration by urothelial cancer
also influences the choice of urinary diversion after
cystoprostatectomy and possibly carrying out excision of
urethra.
Another problem seems to be the presence of pro-
static adenocarcinoma. Referring to the results of the
following research, it can be stated that patients with
bladder cancer stage pT4 have significantly worse distant
results than patients with co-existing prostate cancer.
Table 2 Postoperative characteristics of patients with bladder cancer infiltrating prostate (group I) and with
co-existing prostate cancer (group II)
Group I (n = 52) Group II (n = 21) p value
Creatinine concentration after the surgery (mg/dl) 1.19 (0.7-2.6) 1.15 (1-1.31) 0.91
Positive surgical margin 9 (17,3%) 0 0.04
Mean number of lymph nodes dissected 20,2 19,6 0,83
Local relapse 2 (3.8%) 1 (4.7%) 0.85
Distant metastases after operation 5 (9.6%) 2 (9.4%) 0.37
Adjuvant chemotherapy 26 (50%) 3 (14,2%) 0,04
Postoperative complications 5 (9.6%) 0 0.14
Death (cancer-specific) 15 (28.8%) 2 (9.5%) 0.07
Follow-up (months) 60.5 (0-76) 83.6 (9-181) 0.09
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prostate cancer in most cases was well differentiated,
with low stage of pathologic advancement. The fre-
quency of prostate cancer co-existence in the specimen
after cystoprostatectomy is approximately 30% - 40%,
out of which only 20% are clinically significant [17-20].
Patients who have been diagnosed with the simulta-
neous existence of both prostate and bladder cancer
require close monitoring, focusing on the possible
relapse of prostate cancer after cystoprostatectomy. In
the following research biochemical recurrence occurred
in 2 (9%) patients after radical cystoprostatectomy.
Urological literature indicates that the number of
relapses in similar cases can be significantly higher, up
to 40%, and death caused by relapses occurs in 17.6% of
patients during 10 years of observation [21].
Due to both aforementioned situations, the risk of
non-radicality of prostate sparing cystectomy is relatively
high. Both the co-existence of prostate cancer and the
infiltration of prostate by urothelial cancer in patients
with infiltrating bladder cancer is a negative prognostic
factor. The abovementioned situations confirm that the
treatment of choice in case of infiltrating bladder cancer
is radical cystoprostatectomy.
Conclusions
1. Incidentally diagnosed prostate cancer in specimen
after cystoprostatectomies carried out due to muscle-
invasive bladder cancer is frequently clinically insig-
nificant and characterized by low progression.
2. The risk of simultaneous prostate cancer in
patients with bladder cancer is so high that perform-
ing prostate sparing cystectomy requires the broad-
ening of preoperative diagnostics and special
indications.
3. Patients with bladder cancer infiltrating prostate
are characterized by much higher percentage of pro-
gression and death in comparison with patients with
co-existing prostate cancer.
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